Skip to main content
Top
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2014

Open Access 01-05-2014 | Original Article

Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo

Authors: L. Saint-Aubert, F. Nemmi, P. Péran, E. J. Barbeau, P. Payoux, F. Chollet, J. Pariente

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2014

Login to get access

Abstract

Purpose

Florbetapir (AV-45) has been shown to be a reliable tool for assessing in vivo amyloid load in patients with Alzheimer’s disease from the early stages. However, nonspecific white matter binding has been reported in healthy subjects as well as in patients with Alzheimer’s disease. To avoid this issue, cortical quantification might increase the reliability of AV-45 PET analyses. In this study, we compared two quantification methods for AV-45 binding, a classical method relying on PET template registration (route 1), and a MRI-based method (route 2) for cortical quantification.

Methods

We recruited 22 patients at the prodromal stage of Alzheimer’s disease and 17 matched controls. AV-45 binding was assessed using both methods, and target-to-cerebellum mean global standard uptake values (SUVr) were obtained for each of them, together with SUVr in specific regions of interest. Quantification using the two routes was compared between the clinical groups (intragroup comparison), and between groups for each route (intergroup comparison). Discriminant analysis was performed.

Results

In the intragroup comparison, differences in uptake values were observed between route 1 and route 2 in both groups. In the intergroup comparison, AV-45 uptake was higher in patients than controls in all regions of interest using both methods, but the effect size of this difference was larger using route 2. In the discriminant analysis, route 2 showed a higher specificity (94.1 % versus 70.6 %), despite a lower sensitivity (77.3 % versus 86.4 %), and D-prime values were higher for route 2.

Conclusion

These findings suggest that, although both quantification methods enabled patients at early stages of Alzheimer’s disease to be well discriminated from controls, PET template-based quantification seems adequate for clinical use, while the MRI-based cortical quantification method led to greater intergroup differences and may be more suitable for use in current clinical research.
Appendix
Available only for authorised users
Literature
1.
go back to reference McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.PubMedCrossRef McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939–44.PubMedCrossRef
2.
go back to reference McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. doi:10.1016/j.jalz.2011.03.005.PubMedCentralPubMedCrossRef McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack Jr CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–9. doi:10.​1016/​j.​jalz.​2011.​03.​005.PubMedCentralPubMedCrossRef
3.
4.
8.
go back to reference Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404–11. doi:10.1001/archneurol.2011.150.PubMedCrossRef Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, et al. Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. Arch Neurol. 2011;68:1404–11. doi:10.​1001/​archneurol.​2011.​150.PubMedCrossRef
13.
go back to reference Saint-Aubert L, Planton M, Hannequin D, Albucher JF, Delisle MB, Payoux P, et al. Amyloid imaging with AV45 ((18)F-florbetapir) in a cognitively normal AbetaPP duplication carrier. J Alzheimers Dis. 2012;28:877–83. doi:10.3233/JAD-2011-111598.PubMed Saint-Aubert L, Planton M, Hannequin D, Albucher JF, Delisle MB, Payoux P, et al. Amyloid imaging with AV45 ((18)F-florbetapir) in a cognitively normal AbetaPP duplication carrier. J Alzheimers Dis. 2012;28:877–83. doi:10.​3233/​JAD-2011-111598.PubMed
14.
go back to reference FDA approves 18F-florbetapir PET agent. J Nucl Med. 2012;53:15N. doi:53/6/15N [pii] FDA approves 18F-florbetapir PET agent. J Nucl Med. 2012;53:15N. doi:53/6/15N [pii]
15.
go back to reference Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, et al. Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2013;40:1122–5. doi:10.1007/s00259-013-2415-x.PubMedCrossRef Booij J, Arbizu J, Darcourt J, Hesse S, Nobili F, Payoux P, et al. Appropriate use criteria for amyloid PET imaging cannot replace guidelines: on behalf of the European Association of Nuclear Medicine. Eur J Nucl Med Mol Imaging. 2013;40:1122–5. doi:10.​1007/​s00259-013-2415-x.PubMedCrossRef
16.
go back to reference Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83:923–6. doi:10.1136/jnnp-2012-302548.PubMedCrossRef Wolk DA, Zhang Z, Boudhar S, Clark CM, Pontecorvo MJ, Arnold SE. Amyloid imaging in Alzheimer’s disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography. J Neurol Neurosurg Psychiatry. 2012;83:923–6. doi:10.​1136/​jnnp-2012-302548.PubMedCrossRef
17.
21.
go back to reference Wallon D, Rousseau S, Rovelet-Lecrux A, Quillard-Muraine M, Guyant-Marechal L, Martinaud O, et al. The French series of autosomal dominant early onset Alzheimer’s disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis. 2012;30:847–56. doi:10.3233/JAD-2012-120172.PubMed Wallon D, Rousseau S, Rovelet-Lecrux A, Quillard-Muraine M, Guyant-Marechal L, Martinaud O, et al. The French series of autosomal dominant early onset Alzheimer’s disease cases: mutation spectrum and cerebrospinal fluid biomarkers. J Alzheimers Dis. 2012;30:847–56. doi:10.​3233/​JAD-2012-120172.PubMed
22.
go back to reference Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17:825–41.PubMedCrossRef Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and accurate linear registration and motion correction of brain images. Neuroimage. 2002;17:825–41.PubMedCrossRef
24.
go back to reference Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89. doi:10.1006/nimg.2001.0978.PubMedCrossRef Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage. 2002;15:273–89. doi:10.​1006/​nimg.​2001.​0978.PubMedCrossRef
26.
go back to reference Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988 Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988
27.
go back to reference Zakzanis KK. Statistics to tell the truth, the whole truth, and nothing but the truth: formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers. Arch Clin Neuropsychol. 2001;16:653–67.PubMedCrossRef Zakzanis KK. Statistics to tell the truth, the whole truth, and nothing but the truth: formulae, illustrative numerical examples, and heuristic interpretation of effect size analyses for neuropsychological researchers. Arch Clin Neuropsychol. 2001;16:653–67.PubMedCrossRef
Metadata
Title
Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo
Authors
L. Saint-Aubert
F. Nemmi
P. Péran
E. J. Barbeau
P. Payoux
F. Chollet
J. Pariente
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2656-8

Other articles of this Issue 5/2014

European Journal of Nuclear Medicine and Molecular Imaging 5/2014 Go to the issue